The PRecIsion Medicine for CardiomyopathY (PRIMaCY©) study is an international multicenter observational cohort study. This study has developed a tool that uses patient variables to predict the sudden cardiac death (SCD) risk in pediatric patients with hypertrophic cardiomyopathy (HCM).

Eligible patients

  • Phenotype-positive patients* with primary HCM
  • <18 years old at diagnosis

* Phenotype-positive = maximal LV wall thickness z-score >2 in an at-risk patient.

Ineligible patients

  • Phenotype-negative patients
  • >18 years old at diagnosis
  • Patients with secondary HCM**

**RASopathies (such as Noonan Syndrome), Metabolic, Neuromuscular or other secondary causes

Open the PRIMaCY© SCD Risk Prediction Tool

Additional ways to access PRIMaCY SCD Risk Calculator:

Free MDCalc mobile app available through Apple App Store and Google Play

MDCalc for EHR available through EPIC Show Room

Dr. Seema Mital (PI)

Dr. Seema Mital, MD, is a Staff Cardiologist and Senior scientist and Professor of Pediatrics at the Hospital for Sick Children, University of Toronto in Ontario, Canada. Dr. Mital’s research focuses on cardiac precision medicine for childhood onset heart disease. The full list of publications and her contact information is available here:


We thank Chun-Po Steve Fan, Emily Somerset and Myriam Lafreniere-Roula (Ted Rogers Computational Program, Ted Rogers Centre for Heart Research, The Hospital for Sick Children, University Health Network) for their collaboration in the analysis, development and implementation of the risk calculator.

Relevant publication

Miron A et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020; 142(3): 217-229.

Read the full publication